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Abstract
Objective: The aim of this study was to assess the association between non-high-density-lipoprotein-cholesterol (non-HDL-
C) and the prevalence of asymptomatic intracranial arterial stenosis (ICAS).
Methods and Results: The Asymptomatic Polyvascular Abnormalities Community (APAC) study is a prospective cohort
study based on the Kailuan district (China) population. A total of 5351 eligible subjects, aged $40, and without history of
stroke or myocardial infarction, were enrolled in this study. Transcranial Doppler Ultrasonography (TCD) was performed on
all enrolled subjects for the evaluation of ICAS presence. Out of 5351 patients, 698 subjects showed evidence of ICAS
(prevalence of 13.04%). Multivariate analysis showed that non-HDL-C is an independent indicator for the presence of ICAS
(OR =1.15, 95%CI: 1.08 – 1.23), but with a gender difference (P for interaction,0.01): in men, non-HDL-C is an independent
indicator for ICAS (multivariate-adjusted OR =1.28, 95%CI: 1.18–1.39), but not in women (multivariate-adjusted OR =1.03,
95%CI: 0.93–1.14). Subjects were divided into five subgroups based non-HDL-C levels and these levels correlated linearly
with the prevalence of ICAS (P for trend ,0.01). Compared with the first quintile, multivariate-adjusted OR (95%CI) of the
second, third, fourth and fifth quintiles were: 1.05 (0.71–1.56), 1.33 (0.91–1.95), 1.83 (1.27–2.63), 2.48 (1.72–3.57), respectively.
Conclusion: Non-HDL-C is an independent predictor of ICAS prevalence in men but not in women, suggesting that non-
HDL-C levels could be used as a surveillance factor in the primary prevention of ischemic stroke, especially in men.
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Introduction
Intracranial arterial stenosis (ICAS) is an important cause of
ischemic stroke and the presence of ICAS is associated with a poor
prognosis [1,2]. In contrast to extracranial atherosclerosis,
intracranial atherosclerosis occurs more commonly in Asian [3].
In China, about 30–40% of ischemic strokes and over 50% of
transient ischemic attacks (TIA) are associated with the presence of
ICAS [1]. Previously identified risk factors for the presence of
asymptomatic ICAS include hyperlipidemia, low-density lipopro-
tein cholesterol (LDL-C) levels, hypertension, smoking and
diabetes [4,5,6,7].
Non-high-density lipoprotein cholesterol (non-HDL-C) is a
composite marker encompassing all atherogenic apoprotein B-
containing lipoproteins, including LDL, very-low-density lipopro-
tein (VLDL), intermediate-density lipoprotein (IDL), lipoprotein
(a), chylomicrons and chylomicrons remnants [8]. Non-HDL-C is
an important risk factor for the onset of ischemic stroke [9,10] and
has been shown to be a better risk factor for coronary heart disease
than LDL-C [11,12,13]. A recent meta-analysis showed that non-
HDL-C levels, as a therapeutic target, were more associated to
cardiovascular outcomes than LDL-C [14].
However, whether there is an association between non-HDL-C
levels and the prevalence of asymptomatic ICAS remains
unknown. The purpose of the present epidemiologic and
observational study was to evaluate whether non-HDL-C levels




The Asymptomatic Polyvascular Abnormalities Community
(APAC) study is a community-based, prospective, long-term
PLOS ONE | www.plosone.org 1 May 2013 | Volume 8 | Issue 5 | e65229follow-up observational study, aiming to investigate the epidemi-
ology of asymptomatic polyvascular abnormalities in Chinese
adults. A total of 5,852 subjects were randomly sampled from our
reference population of 101,510 participants (81,110 males and
20,400 females, aged 18–98 years old) from the Kailuan study[15],
which was an ongoing prospective study conducted in 2006 in the
Kailuan community owned and managed by the Kailuan
Company. The Kailuan Company was founded in 1878, and is
located in Tangshan city, a large and littoral modern city located
southeast of Beijing. In addition to coal products, the Kailuan
Company also manages manufactures, construction activities,
electric power, coking, new building materials, chemical industries,
bauxite mining, transportation, trading, etc. This study population
was selected because of an excellent collaboration from partici-
pants and of a good compliance to follow-up visits. Furthermore,
because of its variety of activities, the Kailuan community includes
individuals from a variety of professional and social classes.
From June 2010 to June 2011, a total of 5816 participants
completed the baseline survey. We excluded 376 subjects who
could not meet the inclusion criteria: 1) aged 40 years or older; and
2) no history of stroke, transient ischemic attack, and coronary
disease at baseline. Finally, a total of 5440 participants were
eligible and included in the study. During the baseline survey, all
participants underwent extensive clinical examination, laboratory
tests and transcranial Doppler (TCD) examinations. We had to
exclude 14 participants with incomplete non-HDL-C data and 75
participants under lipid-lowering treatment, leaving 3215 men and
2136 women available for analysis. The study was performed
according to the guidelines from the Helsinki Declaration and was
approved by the Ethics Committees of the Kailuan General
Hospital and the Beijing Tian Tan Hospital. Written informed
consent was obtained from all participants.
Measurement of Indicators
A questionnaire was used to obtain information on enrolled
subjects, including age, gender, hypertension, diabetes, smoking,
and medications prescribed by physicians. Smoking status was
classified into ‘‘non-smoking’’ and ‘‘smoking’’ according to self-
reported information.
Hypertension was defined based on: personal history of
hypertension, a systolic blood pressure $140 mmHg, a diastolic
pressure $90 mmHg, or currently taking antihypertensive med-
ication prescribed by a physician. Subject height was measured
and body mass index (BMI) was calculated as body weight (kg)
divided by the squared height (m
2).
Diabetes mellitus was diagnosed if the subject was undergoing
treatment with insulin or oral hypoglycemic agents, if fasting blood
glucose (FBG) levels were .126 mg/dl, or if he had a personal
history of diabetes mellitus.
Physical examination
Blood pressure was measured in the sitting position and an
average of two readings was used for the current study. If the two
measurements differed by more than 5 mm Hg, a third reading
was then taken, and the average of the three readings was used.
Biochemical Index
Blood was drawn after an overnight fast. Plasma samples were
prepared and analyzed within 4 h of preparation. Total cholesterol
was measured using the endpoint test method [16]. High-density
lipoprotein cholesterol (HDL-C) and LDL-C levels were measured
using a direct test method [17] and triglycerides (TG) were
measured using the GPO method [18] (inter-assay coefficient of
variation: ,10%; Mind Bioengineering Co. Ltd, Shanghai,
China). All blood samples were analyzed using a Hitachi 747
auto-analyzer (Hitachi, Tokyo, Japan) at the Kailuan General
Hospital central laboratory. Non-HDL-C levels were determined
by subtracting serum HDL-C levels from total cholesterol [19].
Fasting blood glucose (FBG) was measured using the hexokinase/
glucose-6-phosphate dehydrogenase method [20].
Trans-cranial Doppler Ultrasonography (TCD)
Examination
TCD was performed by two experienced neurologists using
portable devices (EME Companion, Nicolet). ICAS diagnosis was
made according to the peak flow velocity criteria that was
published and validated against MR angiography and clinical
outcomes [21,22]. Briefly, the occlusive arteries were defined by a
peak systolic flow velocity of: .140 cm per second for the middle
cerebral artery, .120 cm per second for the anterior cerebral
artery, .100 cm per second for the posterior cerebral artery and
vertebra-basilar artery, and .120 cm per second for the siphon
internal carotid artery. Figure 1 depicts a normal TCD waveform
of middle cerebral artery and a typical TCD waveform indicative
of ICAS in the middle cerebral artery. In addition to the above
criteria, patients’ age, presence of disturbance in echo frequency,
turbulence and whether the abnormal velocity was segmental were
also taken into consideration for ICAS diagnosis. Subjects without
a good temporal window were considered without stenosis.
Patients were classified as having occlusive disease if at least one
of the studied arteries showed evidence of stenosis or occlusion.
Statistical analysis
We classified the participants into 5 groups according to serum
non-HDL-C quintiles. Continuous variables were compared using
analysis of variance (ANOVA) and categorical variables were
compared using chi-square tests. The age- and gender-adjusted or
multivariate-adjusted odd ratios (ORs) and 95%CI were calculat-
ed using logistic regression models. The multivariate-adjusted
model was further adjusted for age, gender, BMI, hypertension,
diabetes, current smoking status, HDL-C levels and triglycerides.
A trend test was used to examine whether there was a dose-
dependent relationship between serum non-HDL-C quintiles and
ICAS prevalence. Categorical data were treated as continuous
data using the median value of non-HDL-C levels in each quintile.
Additionally, gender and other potential indicators were also
evaluated to assess if there was any significant interaction between
these variables and the relationship between non-HDL-C levels
and ICAS presence. All statistical analyses were performed using




Based on TCD results, 698 patients were diagnosed with ICAS,
representing a prevalence of 13.0% (698/5351). ICAS patients
included 342 with middle cerebral artery stenosis (6.4%), 230 with
anterior cerebral artery stenosis (4.3%), 58 with posterior cerebral
artery stenosis (1.1%), 66 with vertebral artery stenosis (1.2%), and
89 with basal artery stenosis (1.7%). (Figure 2)
Baseline characteristics
Subjects’ baseline characteristics are presented in Table 1. The
median values of the baseline characteristics are presented for the
non-HDL-C levels quintiles subgroups. Non-HDL-C median
values were 89.4 mg, 112.3 mg, 128.9 mg, 149.0 mg, and
180.0 mg for quintiles 1 to 5, respectively. There were significant
Cholesterol and Intracranial Arterial Stenosis
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triglycerides among quintiles (P,0.01). Absolute values of all these
variables, with the exception of HDL-C, continuously increased as
non-HDL-C levels increased. In contrast, serum HDL-C levels
were lower with higher levels of non-HDL-C. A larger proportion
of subjects with higher non-HDL-C levels were men, smokers and
had concomitant hypertension and diabetes.
Correlation between baseline lipid levels and the
prevalence of ICAS
As shown in Table 2, we observed that non-HDL-C is an
independent indicator for the presence of asymptomatic ICAS
(multivariate-adjusted OR =1.15, 95%CI: 1.08 – 1.23). The
positive associations between non-HDL-C levels and ICAS
diagnosis remained significant after adjustment for age, gender,
HDL-C, triglycerides, BMI, smoking, hypertension and diabetes
(P for trend ,0.01). Compared with quintile 1, prevalence of
asymptomatic ICAS was significantly higher in the fourth and fifth
quintiles after adjustment for the aforementioned confounding
factors (OR=1.48, 95%CI: 1.12–1.94; OR= 1.67, 95%CI: 1.26–
2.20, respectively). In contrast, multivariate analyses showed that
the prevalence of ICAS was increased with increasing LDL-C
levels (P for trend ,0.01). However, compared with the first
quintile, the prevalence of asymptomatic ICAS was not signifi-
cantly higher in the fourth and fifth quintiles (OR=1.21, 95%CI:
0.94–1.56; OR= 1.29, 95%CI: 0.99–1.66, respectively), suggest-
ing that LDL-C levels may not accurately predict ICAS presence.
Figure 1. Normal and typical TCD waveform indicative of ICAS in the middle cerebral artery.
doi:10.1371/journal.pone.0065229.g001
Figure 2. The number (percentages) of stenosis in each vessel
segment. MCA: middle cerebral artery, ACA: anterior cerebral artery,
PCA: posterior cerebral artery, VA: vertebral artery, BA: basal artery.
doi:10.1371/journal.pone.0065229.g002
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in the association between non-HDL-C and presence of asymp-
tomatic ICAS between men and women (P for interaction ,0.01),
and that the association was statistically significant in men only (P
for trend ,0.01). Our results indicated that in men, the prevalence
of ICAS was significantly increased with increasing baseline non-
HDL-C levels (OR=1.28, 95%CI: 1.18–1.39). In contrast, in
women, non-HDL-C levels were not an independent indicator for
the presence of asymptomatic ICAS (OR=1.03, 95%CI: 0.93–
1.14).When other baseline characteristics (including age, BMI,
hypertension, diabetes, and smoking status) were evaluated, our
results indicated that the presence or absence of these indicators
did not influence the association between non-HDL-C levels and
the prevalence of asymptomatic ICAS (P =0.08, 0.42, 0.26, 0.07,
and 0.11 respectively) (Table 3).
Discussion
In this study, we observed that non-HDL-C, but not LDL-C,
levels were an independent indicator for the prevalence of
asymptomatic ICAS in men, but not in women. To the best of
our knowledge, this is the first evidence specifically showing the
significant association between non-HDL-C levels and the
prevalence of asymptomatic ICAS.
Currently, digital subtraction angiography (DSA), magnetic
resonance angiography (MRA) and TCD are methods commonly
used to detect and diagnose ICAS. DSA and MRA are not suitable
for large epidemiological survey mainly because they are invasive
and have to be used in an inconvenient setting. Furthermore,
results from a previous study showed that compared with MRA,
TCD had a higher sensitivity and specificity for ICAS detection.
The sensitivity and specificity of TCD in diagnosing ICAS are
91.4% and 82.7% respectively [23]. TCD is therefore currently
considered to be the best method for the continuous monitoring of
cerebral hemodynamics as it is non-invasive, simple, and
convenient to use with excellent results repeatability [24].
The current study indicated that ICAS prevalence was 13.4% in
our study population, which is higher than what was reported from
another study conducted in China in 2007 and using a similar
study population as well as the same diagnosis criteria for ICAS.
The study included 590 asymptomatic villagers aged $40 years in
rural China and reported an ICAS prevalence of 6.9% [21].
Previous studies assessed the prevalence of symptomatic ICAS in
different populations. Tsivgoulis et al. [25] evaluated 467
consecutive patients with ACI (60.4% men, mean age 58 +/– 14
years) in Caucasians, and found that symptomatic intracranial
atherosclerosis was documented in 43 patients (9.2%; 95%CI:
6.9%–12.2%). The most common symptomatic intracranial
Table 1. Median baseline characteristics of participants




Q1 Q2 Q3 Q4 Q5
N 1070 1070 1071 1070 1070
Age, years 50.0 50.7 51.6 53.6 55.0 ,0.01
Women, % 45.3 41.1 37.2 36.5 39.4 ,0.01
Smoking, % 26.6 31.7 33.1 33.4 35.8 ,0.01
Hypertension, % 38.7 44.0 47.6 54.1 54.1 ,0.01
Diabetes, % 7.57 9.53 11.2 14.0 17.1 ,0.01
Body mass index, kg/m
2 23.9 24.5 24.7 25.3 25.4 ,0.01
Total cholesterol, mg/dl 154.7 173.2 188.7 208.8 242.1 ,0.01
HDL-C, mg/dl 66.5 61.1 59.6 58.1 58.1 ,0.01
Triglycerides, mg/dl 85.9 101.9 110.8 133.8 164.8 ,0.01
Non-HDL-C: non-high-density lipoprotein cholesterol; HDL-C: high-density
lipoprotein cholesterol
doi:10.1371/journal.pone.0065229.t001
Table 2. Odd ratios (OR) for ICAS according to baseline blood lipid levels quintiles.




Q1 89.4 107 (10.0%) 1 1
Q2 112.3 112 (10.5%) 1.08 (0.81–1.43) 1.03 (0.77–1.38)
Q3 128.9 119 (11.1%) 1.11 (0.84–1.47) 1.06 (0.79–1.41)
Q4 149.0 169 (15.8%) 1.60 (1.23–2.08) 1.48 (1.12–1.94)
Q5 180.0 191 (17.9%) 1.74 (1.35–2.26) 1.67 (1.26–2.20)
P for trend P,0.01 P,0.01
Continuous Scale 1.17 (1.10–1.24) 1.15 (1.08–1.23)
LDL-C
Q1 66.5 136 (12.9%) 1 1
Q2 87.8 117 (10.7%) 0.87 (0.67–1.14) 0.88 (0.67–1.16)
Q3 100.5 117 (11.1%) 0.96 (0.73–1.26) 0.93 (0.71–1.22)
Q4 113.7 157 (14.6%) 1.26 (0.98–1.62) 1.21 (0.94–1.56)
Q5 136.9 170 (16.1%) 1.35 (1.05–1.73) 1.29 (0.99–1.66)
P for trend P,0.01 P,0.01
Continuous Scale 1.10 (1.04–1.17) 1.09 (1.03–1.15)
95% CI, 95% confidence interval; non-HDL-C, non-high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.
*Model 1: adjusted for age, and gender.
{Model2: adjusted for age, gender, BMI, hypertension, diabetes, smoking, HDL-C and triglycerides.
doi:10.1371/journal.pone.0065229.t002
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followed by terminal internal carotid artery (18.8%). Arenillas
et al. [26] reported a symptomatic middle cerebral artery stenosis
prevalence of 5.6% in Spain. Meseguer et al. [27] showed that the
prevalence of symptomatic ICAS was 8.8% in France. However, it
is important to note that these studies examined ICAS in
symptomatic populations of patients, while the present study
examined asymptomatic ICAS in a general population.
It is possible that the prevalence of ICAS increased in the past
five years, which would not be surprising considering the fact that
the incidence of dyslipidymia and associated cardiovascular
diseases are increasing in modern China [22,28]. Although BMI,
smoking and age were comparable between the present study and
the study by Wong et al. [20], there was more hypertensive
subjects in the present study (47.7% vs. 22.2%) and slightly more
diabetic subjects (11.9% vs. 8.0%). These two differences could
explain, at least in part, the increase in asymptomatic ICAS
prevalence observed in the present study. Together with our
findings that the middle cerebral artery being consistently the most
common region of intracranial arterial stenosis, our study provided
strong supportive evidence for the importance of identifying
indicators associated with the presence of ICAS. However,
prospective studies are needed to correctly assess the development
of ICAS.
Currently, there are few studies on the relationship between
serum lipid levels and ICAS presence. Previous studies in Chinese
showed that hyperlipidemia [2] and LDL-C [5] were important
risk factors for ICAS. A study conducted in a Korean population
also showed that hypercholesterolemia was an independent ICAS
risk factor in men [29]. Additionally, serum lipoprotein (a) was also
considered as a predictor for intracranial and extra-cranial arterial
stenosis in patients with ischemic stroke [30]. However, whether
there was an association between non-HDL-C levels and the risk
of developing ICAS was not clear. It is worth mentioning that we
excluded subjects who were under treatment with lipid-lowering
agents; so, measured baseline non-HDL-C levels represent the true
levels in our patients.
Non-HDL-C is a mixture of multiple atherogenic apoprotein B-
containing lipoproteins, LDL, VLDL, IDL, chylomicrons, chylo-
microns remnants, and lipoprotein (a). Previous studies showed
that non-HDL-C was an important risk factor for ischemic stroke
[9,10]. Furthermore, the predictive value of non-HDL-C for
coronary heart disease is higher than LDL-C [11,12,13]. LDL-C is
a well- and long-known risk factor for vascular diseases [8], and
our study showed that LDL-C levels are indeed associated with the
prevalence of ICAS, but that it was significant only for the highest
quintile. However, LDL particles are not the only atherogenic
apoprotein B-containing lipoproteins in circulation; indeed, studies
showed that VLDL, IDL and chylomicron remnants also
participate to atherosclerosis [8]. Since LDL-C levels are included
in non-HDL-C levels, and since our results showed a better
association between non-HDL-C levels and the presence of ICAS,
our study provided supportive evidences for this concept as high
non-HDL-C levels showed a better association with the presence
of asymptomatic ICAS in our study population than LDL-C levels.
Recently, the American Diabetes Association and the American
Heart Association reached an agreement for lipid management in
high-risk patients, in which non-HDL-C is considered better than
LDL-C in identifying high-risk patients; it is also recommended
that non-HDL-C levels are the primary goal for lipid lowering
therapy in high-risk and dyslipidemic patients [31]. From this
perspective, our study provided valuable supportive evidence that
non-HDL-C should be closely monitored and treated, particularly
Table 3. Multivariate-adjusted odd ratios
* (OR) for ICAS according to non-HDL-C levels, stratified by gender and selected risk
factors.
non-HDL-C, quintiles P for trend Continuous Scale P interaction
Q1 Q2 Q3 Q4 Q5
Gender P,0.01
Men 1 1.05 (0.71–1.56) 1.33 (0.91–1.95) 1.83 (1.27–2.63) 2.48 (1.72–3.57) P,0.01 1.28 (1.18–1.39)
Women 1 1.06 (0.69–1.62) 0.87 (0.55–1.37) 1.26 (0.82–1.95) 1.04 (0.66–1.64) P=0.62 1.03 (0.93–1.14)
Age p=0.08
,60 1 1.10 (0.76–1.58) 0.96 (0.66–1.40) 1.70 (1.20–2.42) 1.44 (0.99–2.10) P,0.01 1.13 (1.04–1.26)
$60 1 0.97 (0.60–1.56) 1.37 (0.87–2.14) 1.39 (0.89–2.16) 2.21 (1.44–3.40) P,0.01 1.23 (1.11–1.35)
Hypertension p=0.42
No 1 1.30 (0.83–2.05) 1.18 (0.74–1.88) 1.75 (1.11–2.76) 1.55 (0.96–2.50) P=0.03 1.12 (1.01–1.25)
Yes 1 0.88 (0.60–1.28) 0.99 (0.69–1.44) 1.36 (0.96–1.92) 1.71 (1.21–2.42) P,0.01 1.18 (1.09–1.28)
Diabetes p=0.26
No 1 1.02 (0.75–1.39) 1.01 (0.74–1.37) 1.39 (1.04–1.88) 1.48 (1.09–2.00) P,0.01 1.12 (1.04–1.20)
Yes 1 1.20 (0.51–2.81) 1.71 (0.76–3.87) 2.32 (1.08–5.00) 3.45 (1.60–7.42) P,0.01 1.39 (1.18–1.62)
Smoking p=0.07
No 1 1.18 (0.85–1.64) 0.99 (0.70–1.39) 1.30 (0.94–1.81) 1.50 (1.08–2.09) P=0.02 1.10 (1.02–1.18)
Yes 1 0.71 (0.39–1.29) 1.29 (0.76–2.21) 1.97 (1.18–3.29) 2.14 (1.27–3.59) P,0.01 1.30 (1.16–1.46)
BMI, kg/m
2 p=0.11
,25 1 0.86 (0.59–1.23) 0.83 (0.59–1.21) 1.20 (0.84–1.71) 1.12 (0.77–1.63) P=0.20 1.06 (0.97–1.15)
$25 1 1.42 (0.86–2.34) 1.56 (0.96–2.54) 2.11 (1.33–3.35) 2.76 (1.74–4.38) P,0.01 1.28 (1.16–1.40)
*Multivariate-adjusted odd ratios (OR): adjusted for age, gender, BMI, hypertension, diabetes, smoking, HDL-C, triglycerides
doi:10.1371/journal.pone.0065229.t003
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population.
Our findings on gender differences in the association between
non-HDL-C levels and the presence of ICAS are also intriguing.
The prevalence of ICAS increases with increasing non-HDL-C
levels in men, while non-HDL-C was not an indicator of ICAS in
women. The differential impact of gender on indicators of ICAS
was previously documented. Kim et al. showed that advanced age,
diabetes and smoking status were independent risk factors for
ICAS in men; in women, only hypertension and diabetes were
independent risk factors for the development of ICAS [29]. The
potential protecting effects of estrogens on atherosclerosis devel-
opment may contribute to the observed differential outcome.
Previous studies showed that the risk of cardiovascular diseases in
premenopausal women was lower than in men of the same age
and than in postmenopausal women. This is because estrogens can
enhance the effect of carbon monoxide-mediated angiotensin,
which has anti-oxidation effect on vascular smooth muscle cells,
thus protecting vascular endothelial function and preventing
atherosclerosis development [32,33,34].
One caveat of the current study is that patients with inadequate
temporal window for TCD analysis were considered in the non-
ICAS group. This may lead to an underestimation of the ICAS
prevalence. Nevertheless, this is the first study investigating the
relationship between non-HDL-C levels and the prevalence of
ICAS in a large population with a high follow-up ratio and
minimal missing information. Additionally, baseline non-HDL-C
levels reflect the true lipid levels because subjects under lipid-
lowering treatment were excluded. Because of the nature of the
Kailuan Company activities, there is an imbalance in gender
distribution in the original Kailuan study, men being much more
represented than female. We partially overcame this limitation by
increasing the women ratio in the APAC study during the random
selection process. Also, participants in the Kailuan study received
free medical examinations and we cannot exclude a selection bias
due to the fact that poorer people were more willing to participate.
However, our large sample size should help to generalize our
results and our sample was randomly selected from the Kailuan
study.
Conclusion
In conclusion, non-HDL-C levels are an independent indicator
of ICAS presence in men. This study provides new evidences
supporting the monitoring of non-HDL-C levels as a primary
endpoint for stroke prevention. We could obtain the non-HDLC
levels by subtracting serum HDL-C levels from total cholesterol; so
the measurement of non-HDL-C levels does not lead to cost
increase for patients or the healthcare system. We suggest that
non-HDL-C evaluation could be used as a screening index as part
of the prevention program for stroke and ICAS. However, more
epidemiological and experimental data are needed to further
confirm this concept.
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